Caption Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Caption Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-194,500	Closed	-$591K	–	2169
2024 Q4	$591K	Buy	+194,500	New	+$847K	0.01%	1058
2023 Q4	–	Sell	-121,900	Closed	-$1.4M	–	1757
2023 Q3	$1.4M	Sell	121,900 -2,000	-2%	-$38.5K	0.02%	679
2023 Q2	$3.14M	Buy	123,900 +30,400	+33%	+$947K	0.06%	390
2023 Q1	$3.01M	Sell	93,500 -247,000	-73%	-$7.7M	0.06%	345
2022 Q4	$6.29M	Sell	340,500 -128,800	-27%	-$2.95M	0.1%	254
2022 Q3	$12.7M	Buy	+469,300	New	+$9.52M	0.17%	120

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caption Management's RVNC Position: Q1 2025 in Review

Caption Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 38,290 shares — an estimated $116K sold.

Caption Management first reported a position in RVNC in Q4 2022 and held it in 4 quarters. The position peaked at $2.72M in Q4 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Caption Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Caption Management sold 38,290 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $116K.
Caption Management first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 4 quarters.
Caption Management's Revance Therapeutics, Inc. position peaked at $2.72M in Q4 2022.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.